INTRODUCTION
============

The main character of eukaryotes is the presence of separated genome containing nucleus from cytoplasm ([@b1-bmb-51-327]). Although there are many merits to the existing nucleus acting as a separated organelle (stable maintenance of genomic material and alternative use of genetic material), the morphology of the nucleus needs to be maintained and the materials should be transported across the nuclear membrane, which is continuous with the Endoplasmic Reticulum (ER; [@b2-bmb-51-327]). To maintain the nuclear morphology and ensure resilience, the intermediate filament mesh in the inner nuclear membrane and the nuclear plasm can also co-evolve with eukaryotic cells. The core components of the nuclear intermediate filaments (IFs) are Lamin A, Lamin C, and Lamin B ([@b3-bmb-51-327]). These proteins are conserved from yeast to mammalian cells ([@b4-bmb-51-327]). However, these proteins do not seem to be part of the simple physical network of the nuclear plasm. Lamin A/C forms a network and is associated with Emerin and the nuclear pore complex ([@b5-bmb-51-327], [@b6-bmb-51-327]). Emerin is a linker between the Lamin A/C mesh and the cytoplasmic actin filament ([@b7-bmb-51-327]). Thus, this interaction may involve the localization of the nucleus in all cells and nuclear movement when cells migrate ([@b8-bmb-51-327]) A more interesting feature is the absence of Lamin A/C expression in stem cells and neurons ([@b9-bmb-51-327], [@b10-bmb-51-327]); these types of cells only express Lamin B as a nuclear IF.

Due to the various functions of Lamin A/C, genetic mutations on Lamin A/C induce a broad range of human genetic diseases (so called laminopathies; [@b11-bmb-51-327]--[@b14-bmb-51-327]). The case of laminopathy is very unusual. In general, mutations on a single gene are involved in a single disease. For example, various types of genetic mutations on p53 are related to cancer or cancer-related pathogenesis ([@b15-bmb-51-327]). However, mutations on Lamin A/C can induce different diseases from premature aging to neuropathy.

In this paper, we discuss the physiological processing of Lamin A/C and the relevance of mutations and laminopathies. We also describe the recent treatment of laminopathies.

LAMIN A PROCESSING
==================

The LMNA gene is located on chromosome 1q21.2 loci and is composed of 12 exons ([Fig. 1](#f1-bmb-51-327){ref-type="fig"}; [@b16-bmb-51-327]). Exons 1--10 between Lamin A and Lamin C are identical ([Fig. 1](#f1-bmb-51-327){ref-type="fig"}) and exons 11 and 12 are specific to Lamin A. Lamin C is produced by unique exon 11, which is transcribed by alternative splicing and translated into only 6 amino acids (VSGSRR; [@b17-bmb-51-327]). Exon 12 on Lamin A possesses a CaaX motif (actual amino acid sequence is CSIM), which is at the end of Lamin A and the farnesylated motif ([@b18-bmb-51-327]). Lamin A is first produced as prelamin A containing the CaaX motif and maturates by protease-mediated cleavage ([@b17-bmb-51-327], [@b18-bmb-51-327]). Thus, matured Lamin A does not have a farnesylated CaaX motif. Zmspte24 has been suggested as the responsible protease for Lamin A maturation ([@b19-bmb-51-327]). Loss of Zmste24 also induces laminopathies (lipodystrophy and dermopathy; [@b20-bmb-51-327], [@b21-bmb-51-327]). Thus, the correct processing of Lamin A is also important for maintaining a healthy cellular condition. The biological function of C-terminal farnesylation would be targeting of Lamin A to nuclear membrane. However, considering that only mature Lamin A mouse expression is indistinguishable from wild type mouse ([@b22-bmb-51-327]), it is unclear why Lamin A is expressed as prelamin A. This implies that matured Lamin A does not work as an attached form of the nuclear membrane. In contrast, the binding of Lamin A (prelamin A) on the nuclear inner membrane may cause problems (laminopathies). The CaaX motif of Lamin B expressed differentially from Lamin A is not eliminated, and Lamin B is associated with the nuclear membrane ([@b23-bmb-51-327]). These results suggest that the primary nuclear IF is the Lamin B mesh. In fact, Lamin B is expressed in all types of cells, including stem cells and neurons. In addition, the rarity of laminopathies by Lamin B mutation also supports the possibility that Lamin B is a more essential IF than Lamin A.

LAMINOPATHIES AND MUTATIONS
===========================

As described previously, mutations on Lamin A or related proteins induce various types of human diseases. These diseases are divided into two large categories: primary laninopathies which are induced by mutations on Lamin A and secondary laminopathies which are caused by mutations on Lamin B (Lamin B1 and Lamin B2), prelamin processing proteins (such as Zmpste24) or lamin binding proteins (such as emerin). To date, more than 400 mutations in the Lamin A gene have been identified from patients. However, each mutation has a very wide range of phenotypes, and the genetic features vary such that in some cases function is gained, while in others function is lost. [Fig. 2](#f2-bmb-51-327){ref-type="fig"} and [Table 1](#t1-bmb-51-327){ref-type="table"} show the mutations of Lamin A and the related diseases. The following section describes several mutations and their relevance to disease symptoms.

MUSCULAR DYSTROPHY
==================

Many types of Lamin A mutations are related to muscular dystrophy. However, the tissues first affected differ from genetic mutations. Commonly called 'muscular dystrophy', the disease was first described in 1955 as Emery-Dreifuss muscular dystrophy (EDMD), which affects 1 in 100,000 births ([@b24-bmb-51-327], [@b25-bmb-51-327]). EDMD is divided into 3 groups as follows. The first group is referred to as autosomal dominant EDMD (AD-EDMD). A large portion of mutations on Lamin A is included in this group. Thus, EDMD-related Lamin A mutations are generally gain-of-function mutations. Numerous mutations have been reported as EDMD-related mutations ([Table 1](#t1-bmb-51-327){ref-type="table"}). The second group is referred to as autosomal recessive EDMD (AR-EDMD). Some types of Lamin A mutations that make stop codon are represented in this group ([@b26-bmb-51-327]). The third group is referred to as X-linked EDMD (XL-EDMD). This type of mutation is caused by a loss of emerin, Lamin A binding protein ([@b25-bmb-51-327], [@b27-bmb-51-327]). Since the emerin gene is located on the X-chromosome, XL-EDMD affects males. Although XL-EDMD causes very severe muscle dystrophy, the emerin knockout mouse model shows a healthy condition with XL-EDMD ([@b28-bmb-51-327]). This demonstrates the genetic difference between human and mouse species.

EDMD primarily affects skeletal muscles, and is detected from teenage years ([@b26-bmb-51-327], [@b29-bmb-51-327]). The characteristic of EDMD is a slow, progressive wasting of skeletal muscles in the shoulder girdle and distal leg muscles. The histological features of the muscles of a person affected by EDMD are various muscle fiber sizes and the mislocalization of the cell nucleus ([@b25-bmb-51-327]--[@b29-bmb-51-327]). Cardiac muscle dystrophy is also observed in EDMD, which differs from dilated cardiomyopathy (CMD) in which skeletal muscles are not affected ([@b26-bmb-51-327], [@b29-bmb-51-327]). Thus, mutations causing EDMD seem to induce broader functional defects than CMD-related mutations. Although CDM is induced by other genes, 5 mutations on Lamin A have been reported to be related to CMD ([@b30-bmb-51-327]). In addition, Lamin A mutations also induce Limb-girdle muscular dystrophy, type 1B, and Malouf syndrome (mutations A57P and L59Rl, [@b31-bmb-51-327]--[@b34-bmb-51-327]). Interestingly, A57P and L59R mutations are also found in atypical Werner syndrome (A57P) and CDM1A (L59R). The reason why identical mutations induce different phenotypes has yet to be found. [Table 1](#t1-bmb-51-327){ref-type="table"} shows the relevance of Lamin A mutations and human laminopathies.

Lipodystrophy
-------------

The clinical feature of Lipodystrophy (LD) is the reduction or loss of subcutaneous adipose tissue ([@b35-bmb-51-327]). Loss of fat has been detected from childhood or early adulthood. Two categories of LD are caused by mutation on Lamin A or related proteins: Familial partial lipodystrophy type 2 (FPLD2) and Mandibuloacral dysplasia (MAD). The main areas of the body affected by AMD are the face, neck and truck. Loss of adipose tissue can cause insulin resistance, and subsequently diabetes. The lipodystrophy-related Lamin A mutations are listed in [Table 1](#t1-bmb-51-327){ref-type="table"}.

Neuropathies
------------

Duplication or overexpression of Lamin B1 induces adult-onset autosomal dominant leukodystrophy (ADLD), which is slowly progressive ([@b36-bmb-51-327], [@b37-bmb-51-327]). Symptoms are therefore apparent in people in their 40s and 50s. On the other hand, Lamin A mutation (R298C) can induce Charcot-Marie-Tooth (CMT) disorder (autosomal recessive CMT2A). However, the reason why the overexpression of the Lamin B1 or Lamin A mutation induces neuropathies has not yet been addressed until now.

Segmental progeroid diseases
----------------------------

Although mutations on Lamin A induce various types of diseases, the most interesting feature is their promotion of premature aging. Since the aging process is believed to be generated by very complicated mechanisms, it is astonishing that a single mutation on Lamin A promotes the aging process.

Hutchinson-Gilford progeria syndrome (HGPS) is a well-known aging related disease ([@b38-bmb-51-327]). HGPS is a very rare genetic disorder (1 in 20,000,000), in which all aging related features are displayed at an early stage, except cancer and neuro-degenerative diseases ([@b38-bmb-51-327]--[@b40-bmb-51-327]). HGPS patients suffer from sarcopenia, lipodystrophy, diabetes, cataracts, and atherosclerosis ([@b41-bmb-51-327]). In general, patients die from cardiovascular complications in their early teenage years ([@b41-bmb-51-327], [@b42-bmb-51-327]). At least 90% of all HGPS cases are caused by a single base pair substitution at exon 11 of the Lamin A gene (c.1824C\>T, p.G608G). Although this mutation does not change the amino acid, it generates a new splicing donor site ([Fig. 2A](#f2-bmb-51-327){ref-type="fig"}). Thus, the product of mutation is 50 amino acid deleted (intra-deletion) abnormal Lamin A, so called progerin ([Fig. 3A](#f3-bmb-51-327){ref-type="fig"}; [@b38-bmb-51-327]). Since 50 amino acid sequences containing Zmpste24-cleavage sites are deleted, progerin is not processed by protease, and the farnesylated CaaX motif remains. Based on this, an attempt has previously been made to use the inhibitor of farnesyl-transferase (lonafarnib) as a treatment for HGPS, although this treatment did not show a favorable outcome ([@b43-bmb-51-327]).

Since many clinical features of HGPS resemble the physiological aging process, many researchers have expressed interest in the molecular mechanism by which progerin promotes aging ([@b44-bmb-51-327]). In fact, in healthy people, progerin expression is detected and increases with the aging process ([@b45-bmb-51-327]). Also, the cellular characteristic of HGPS, nuclear blebbing, is detected in normally aged cells ([Fig. 3B](#f3-bmb-51-327){ref-type="fig"}), supporting the belief that the aging process induced by HGPS is a phenocopy of the physiological aging process. In addition to progerin production, several mutations have been reported to be related to HGPS.

Among the secondary laminopathy, *Zmpste24* deletion is also related to segmental progeroid syndrome, Restrictive Dermopathy (RD; [@b46-bmb-51-327]). Usually, RD patients die within a few weeks of birth due to respiratory failure ([@b47-bmb-51-327]). However, the Zmpste24−/− mouse can live longer than 6 months, although it has a small body size and aging-related phenotypes. This difference raises a new question about how the mouse model can accurately show the disease-phenotype of humans, and further indicates the difference between human and mouse systems. Along with HGPS, Werner syndrome (WS) is another well-known premature aging disease ([@b48-bmb-51-327]). Since premature aging features are displayed after puberty, it is called the 'progeria of the adult'. Although clinical features are detected after puberty, WS shows all of the aging features, such as skin atrophy, ulcers, cataracts, type 2 diabetes mellitus, sarcoma, etc. ([@b49-bmb-51-327], [@b50-bmb-51-327]). Thus, WS is also believed to be a useful model for studying the physiological aging process with HGPS. Although it is a rare genetic disorder, the incidence of WS is unusually high in Japan ([@b51-bmb-51-327]). Causal mutation of WS is a loss of the WRN gene which encodes a DNA helicase, and is included in the RecQ4 family ([@b48-bmb-51-327]). Although about 80% of WS cases are caused by WRN mutation, the remaining 20% do not harbor the WRN mutation (atypical Werner syndrome: AWS; [@b52-bmb-51-327]). Among the WS cases, a small portion (about 20%) has mutations on Lamin A ([Table 1](#t1-bmb-51-327){ref-type="table"}). These features suggest that some types of Lamin A mutations can disrupt the function of WRN.

MOUSE MODEL FOR LAMINOPATHIES
=============================

Mouse models are widely used to understand the physiological and pathological mechanism of human genes. The appropriate mouse model is critical in drug development for human diseases. Consequently, many trials have been performed to create a mouse model for human laminopathies. The following section summarizes the laminopathy-related mouse models.

Lamin A related knockout models ([Table 2](#t2-bmb-51-327){ref-type="table"})
-----------------------------------------------------------------------------

To address the function of Lamin A, a Lamin A/C knockout mouse has been developed by the disruption of exon 8 to exon 11 ([@b53-bmb-51-327]). The elimination of all Lamin A and Lamin C shows growth retardation and loss of body weight. Collectively, Lamin A/C deletion induces EDMD-like phenotypes. However, heterozygous mice do not show any pathological features, indicating that a single copy of LMNA is sufficient for normal function performance. In contrast to total Lamin A/C deletion, the Lamin A deleted mouse model (generated by the deletion of exon 11) does not show apparent abnormalities ([@b56-bmb-51-327]). This result implies that, at least in the mouse model, Lamin A is dispensable for normal development when Lamin C is normally expressed. In addition, a functional redundancy exists between Lamin A and Lamin C. The most interesting mouse model is *Lmna^LAO/LAO^* ([@b22-bmb-51-327]). While this mouse expresses only matured Lamin A, it is entirely normal with a nuclear defect in the fibroblast. This result leads to the same conclusion that, at least in the mouse system, prelamin A is dispensable for normal development. In fact, if Lamin A does not contain exon11 and 12, it is almost identical to Lamin C. In contrast, Zmpste24 knockout mice display progeria-like phenotypes such as growth retardation, muscular dystrophy, and short life span (6--7 months). Thus, this model has been used for the study of HGPS. However, as described above, Zmpste24 deletion evokes RD.

From the knockout mouse model of Lamin A or Zmpste24, normal function of Lamin A is required for normal development and preventing progeria features.

An emerim knockout mouse model has also been developed to study EDMD ([@b57-bmb-51-327], [@b58-bmb-51-327]). However, in contrast to human EDMD, complete emerin knockout does not produce EDMD phenotype. This result suggests that the regulation mechanism of Lamin A or nuclear IF between human and mouse significantly differs.

Lamin A Mutant knock-in mouse model ([Table 3](#t3-bmb-51-327){ref-type="table"})
---------------------------------------------------------------------------------

Since EDMD or lipodystrophy is an autosomal dominant pattern, to mimic these features, several types of transgenic mouse models have been proposed ([@b59-bmb-51-327]--[@b67-bmb-51-327]). Curiously, AD-EDMD related mutations do not induce the EDMD phenotype in the knock-in mouse model. For example, *Lmna^wt/H222P^* mice show a phenotype undisguisable from wild type mice ([@b62-bmb-51-327]), even though this mutation induces AD-EDMD. Instead, *Lmna^H222P/H222P^* mice (homozygous mice) display EDMD phenotypes such as muscle dystrophy and lipodystrophy. We can find a similar pattern in other types of mouse model ([Table 3](#t3-bmb-51-327){ref-type="table"}). These differences strongly suggest a fairly significant difference between human and mouse systems.

Among the various knock-in mouse models, the *Lmna^G609G^* model has recently been intensively studied because it closely copies the human HGPS ([@b67-bmb-51-327]). Although this model shows the same limitation, *Lmna^G609G/G609G^* also shows very similar HGPS features such as obvious growth retardation, cardiovascular defects, and very short life span. Thus, using this model, intensive screening and development of new drugs for HGPS are currently being carried.

In addition to the knock-in mouse model, Lamin B1 mouse models have been generated ([Table 4](#t4-bmb-51-327){ref-type="table"}) since easily eliminated Lamin B1 induces an embryonic lethal phenotype (or neonatal lethal; [@b68-bmb-51-327]). In contrast, the overexpression of Lamin B1 induces ADLD, which is consistent with human disease features ([@b69-bmb-51-327]).

CURRENT TREATMENT OF LAMINOPATHIES
==================================

Until now, an appropriate treatment for the fundamental pathogenic mechanism of laminopathies has not been suggested. Today, treatment for laminopathies is limited to relieving symptoms. Corrective surgery can be used for distorted body shape in EDMD ([@b70-bmb-51-327]) and coronary artery bypass surgery can be performed for HGPS ([@b71-bmb-51-327]). However, none of these treatments can cure the roots of these diseases.

For EDMD, the partial effect of rapamycin has been reported in a EDMD mouse model ([@b72-bmb-51-327], [@b73-bmb-51-327]). However, long term treatment of rapamycin can induce side effects such as lung toxicity, insulin resistance, and cataract. Thus, rapamycin is not an appropriate drug for EDMD.

Since farnesyl-residue is retained in progerin, lonafarnib (an inhibitor of farnesyl-transferase) has been used in the treatment of HGPS patients ([@b74-bmb-51-327]). Indeed, lonafarnib showed a favorable effect on nuclear morphology in a cell experiment ([@b75-bmb-51-327]). In addition, this chemical improved the disease phenotype in the Zmste24−/− mouse model ([@b76-bmb-51-327]). However, a phase II clinical trial with HGPS patients did not show any therapeutic effect ([@b43-bmb-51-327], [@b77-bmb-51-327]). Since lonafarnib has been developed as an anti-cancer drug, it is toxic to normal cells, rendering long-term treatmentimpossible. Indeed, long term treatment of lonafarnib induces a donut-shaped cell nucleus and defects in cell division ([@b78-bmb-51-327]). Considering the above, the treatment of lonafarnib for HGPS is not reasonable.

The co-treatment of lonafarnib and rapamycin has recently been suggested, and a clinical trial is on-going by the Progeria Research Foundation ([@b43-bmb-51-327]). However, as described above, the lonafarnib and rapamycin chemicals are not suitable for long-term treatment and they cannot correct the basic mechanism of HGSP. Antisense oligonucleotide has also been proposed for treatment of HGPS ([@b79-bmb-51-327]), and has been shown to extend the life span of a HGPS mouse model (*Lmna^G609G/G609G^*) by about 4 weeks (average life span: 16 weeks vs. 20 weeks; [@b80-bmb-51-327]). However, until now, it has been impossible to deliver the antisense oligonucleotide to all tissues. Other approaches are currently being made to find a drug for HGPS, for example by generating a new drug for HGPS based on a novel pathological mechanism. The previous pathogenic mechanism is the accumulation of pre-lamin A and retention of farnesyl-residue. However, while Zmspte24−/− induces RD, it does not induce HGPS. This implies that progerin, a causal product of HGPS, has a unique pathological mechanism. A recent study suggested that progerin shows a very strong binding affinity with wild type Lamin A and disrupts the nuclear membrane structure ([@b45-bmb-51-327]). A new progerin-Lamin A binding inhibitor (small chemical) has thus been proposed as a candidate drug for HGPS ([@b45-bmb-51-327]). The treatment of HGPS with this chemical can extend the life span provided the antisense oligonucleotide treatment is carried out using the *Lmna^G609G/G609G^* mouse model. Moreover, an increase of the chemical dose can extend the life span up to 27 weeks ([Fig. 4](#f4-bmb-51-327){ref-type="fig"}; [@b45-bmb-51-327]). Thus, this chemical could be a strong candidate drug for HGPS.

CONCLUSION
==========

In this paper, we described laminopathies and mutations. Mutations on Lamin A or related genes induce a very diverse spectrum of human diseases ranging from muscular dystrophy to progeria. In addition, we found that some mouse models are inappropriately matched for human disease due to the different systems or different roles of Lamin A among organisms. It would thus be beneficial to understand why and how Lamin A mutations on different sites or even in the same site generate different human pathologies. Until now, no clear answer on this has been presented.

Lamin A is normally processed through a multi-step process as follows. Prelamin A develops into mature Lamin A and forms the dimer. The dimerized Lamin A then develops into tetramerization by dimer-dimer interaction. Tetramerized Lamin A then forms the mesh network with Lamin A or with other linker proteins such as emerin. Therefore, each residue of Lamin A is important for each step. However, we did not know the exact mechanism of Lamin A mesh processing. In addition, Lamin A tends to hold the chromosome to retain chromosomal territory. Thus, if we know the exact molecular mechanism of Lamin A processing and function, we could develop more effective drugs for laminopathies.

Laminopathies are a group of very rare genetic disorders. However, they are involved in various types of diseases. As shown above, the progerin-mediated aging process is believed to be useful for understanding the general aging process. Similarly, laminopathy-related EDMD is possibly related to aging-induced sarcopenia or cardiac diseases. Thus, understating of the molecular mechanism of laminopathies would be useful for the investigation of other chronic diseases including diabetes and aging.
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![Structure of LMNA gene. LMNA, encoding Lamin A/C is composed of 12 exons and the two produced proteins, Lamin A and Lamin C. Exon 1--10 are commonly used for Lamin A and C proteins. However, exon 11 and 12 are only used by Lamin A. Since the end of exon 12 encodes CaaX motif (actually CSIM), only Lamin A is a target for farnesyl-transferase. In addition, the Zmpste24 protease target sequence is located in exon 11. Thus, Farnesylated Lamin A (prelamin A) is processed into mature Lamin A. Lamin C is produced by Exon 1--10 differentially from Lamin A. However, the final exon is differentially used from lamin by alternative splicing (dark blue box in middle panel). Consequently, the six C-terminal amino acids (VSGSRR; dark blue box) are uniquely derived from Lamin A. We also showed the structural domains of Lamin A/C.](bmb-51-327f1){#f1-bmb-51-327}

![Mutations on Lamin A. To date, more than 400s mutations have previously been found in Laminopathies. Mutations are widely distributed throughout the entire Lamin A gene. See [table 1](#t1-bmb-51-327){ref-type="table"} for co-relationship between mutations and diseases.](bmb-51-327f2){#f2-bmb-51-327}

![Lamin A processing and nuclear deformation. (A) Lamin A processing. After translation, farnesyl-transferase attaches Farnesyl-residue to CaaX motif at C-terminal end. However, protease such as Zmpste 24 cleaved the C-terminal domain. Thus, matured Lamin A does not contain Farnesyl-residue (left progression). In contrast, mutation on G609G (causal mutation of HGPS) generated an abnormal splicing donor on exon 11 and produced progerin. Since progerin still possesses CaaX motif, it is farnesylated. However, this protein no longer has the Zmpste24 cleavage site. Thus, progerin has farnesyl-residue. (B) Nuclear morphology of HGPS cells (right panel). Compared to the normal cell (left panel), the nuclear membrane of this cell showed irregularity and several knots. Green indicates Lamin A/C.](bmb-51-327f3){#f3-bmb-51-327}

![Life span of HGPS mouse model. Lmna G609G/G609G mice showed a very short life span (average life span is 16 weeks). Treatment of Lamin A-progerin binding inhibitor (JH4) could extend life span up to 27 weeks. Chemicals were injected via intraperitoneal injection (i.p) with the indicated concentration (twice/week).](bmb-51-327f4){#f4-bmb-51-327}

###### 

Relevance of Lamin A mutations and human laminopathies

  Muscular dystrophy   Neuropathy   Lipodystrophy   Segmental progeroid                                                                  
  -------------------- ------------ --------------- --------------------- ------- ------ ------- ------- ------- ------- ------- ------- -------
  Q6X                  E203K        Q6X             G232E                 G449D   A57P   N39S    R25G    R298C   R25W    V440M   A57P    T10I
  R25G                 E203G        R25P            L248P                 R453W   L59R   R50P    Y259X           R60G    R471C   R133L   S143E
  R25W                 L215P        R25G            R249Q                 L454P          R249W   E358K           R62G    R527C   L140R   S143F
  L59R                 R225X        E33G            R249W                 N456I          L302P   R377H           ΔK208   R527H   D300N   E145K
  R60G                 Y267C        L35V            F260L                 N456K          E358K   R377L           D230N   A529V   Q656Q   R471C
  E82K                 E317K        N39S            Y267C                 D461Y          L380S   R399C           G456D                   R527C
  L85R                 A347K        A43T            S268P                 W467R          R453P   Y481H           R482W                   T528M
  R89L                 R349L        Y45C            L271P                 I469T          R455P                   R482Q                   M540T
  K97E                 Q355X        R50S            Q294P                 W520S          N456D                   R482L                   K542N
  S143P                R399C        I63S            S295P                 R527P                                  P485R                   E578V
  E161K                R435C        I63N            S303P                 T528K                                  K486N                   V607V
  R190W                R541C        E65G            R336Q                 T528R                                  S573L                   G608S
  D192G                R541S        R89C            R343Q                 L529P                                  R582H                   G608G
  N195K                S573L        R133P           E358K                 L530P                                  R584H                   T623S
                       R644C        L140P           E361K                 R541H                                                          
                                    T150P           M371K                 R541S                                                          
                                    R189P           R377L                 R541P                                                          
                                    R190Q           R386K                 G602S                                                          
                                    R196S           R401C                 R624H                                                          
                                    H222P           V442A                                                                                
                                    H222Y           D446V                                                                                

CDM1A: Cardiomyopathy, dilated, 1A, EDMD: Emery-Dreifuss Muscular dystrophy, MLF: Malouf syndrome, MDC: Muscular dystrophy, congenital, LGMD1B: Muscular dystrophy, limb-gardle, type 1B, CMT1B1: Charcot-Marie-Tooth disease, type 2B1, FDLD2: Lipodystrophy, familial partial, 2, MAD: Mandibuloacral dysplasia lipodystrophy, AWS: Atypical Werner syndrome, HGPS: Hutchinson-Gilford progeria syndrome.

###### 

List of knockout mouse model of Lamin A or related proteins

  Abbreviation    Mutation                                                                                 Homozygous Mouse Phenotype                                                                           Heterozygous Mouse Phenotype   Disease in Human   Ref
  --------------- ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------ ------------------ -------------------------------------
  Lmna^−/−^       Destruction of exons 8 to part of 11 by using insertion of neomycin resistant cassette   Growth rate retardation. Body weight loss. Emery-Dreifuss muscular dystrophy (EDMD)-like phenotype   No apparent abnormalities      Not described      [@b53-bmb-51-327]
  Zmpste24^−/−^   Deletion of exons 2, 3 using insertion of neomycin resistant cassette                    Growth rate reduction. Pre-mature aging                                                              No apparent abnormalities      Not described      [@b54-bmb-51-327]
  Lmna^GT\ −/−^   A promoter trap insertion into intron 2 resulting in a Lamin A-pgeo fusion allele        Cardiac hypertrophy causing functional failure. Skeletal muscle hypotrophy.                          No apparent abnormalities      Not described      [@b55-bmb-51-327]
  Lmna^LCO/LCO^   Deletion of last 150 nucleotides of exon 11 and deletion of intron 11                    No apparent abnormalities                                                                            No apparent abnormalities      Not described      [@b56-bmb-51-327]
  Lmna^LAO/LAO^   Mature Lamin A only                                                                      No apparent abnormalities                                                                            No apparent abnormalities      Not described      [@b22-bmb-51-327]
  EDM−/−          Emerin deletion                                                                          No apparent abnormalities (slight retardation on muscle regeneration)                                No apparent abnormalities      EDMD               [@b57-bmb-51-327],[@b58-bmb-51-327]

###### 

List of point mutant mouse model for laminopathies

  Abbreviation                    Mutation                                                 Homozygous Mouse Phenotype                                                                                                                                                      Heterozygous Mouse Phenotype                                                                                                                 Disease in Human                                                                                            Ref
  ------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -------------------
  ΔK32                            Deletion of K32 in the N-terminal domain of lamins A/C   Kinked tail. Growth retardation. Stagnation in weight gain. Congenital muscular dystrophy.                                                                                      Indistinguishable phenotype                                                                                                                  Congenital muscular dystrophy.                                                                              [@b59-bmb-51-327]
  Disheveled hair and ear (Dhe)   Sponteneous L52R mutation                                Defect in bone mineralization, and low collagen expression causing abnormal morphology of skull, jaws, and ears. Low bone mineral density.                                      Defect in bone mineralization, and low collagen expression causing abnormal morphology of skull, jaws, and ears. Low bone mineral density.   Not described                                                                                               [@b60-bmb-51-327]
  N195K                           Missense mutaiton                                        Weight loss. Shortened lifespan. Dilated cardiomyopathy (DCM)-like phenotype                                                                                                    Not described                                                                                                                                Dilated cardiomyopathy (DCM)                                                                                [@b61-bmb-51-327]
  H222P                           Missense mutaiton                                        Indistinguishable phenotype during sexual maturity stage. Weight loss and reduced growth rate in adult stages. Cardiac dysfunction. Skeletal muscle dystrophy. Lipodystrophy.   Indistinguishable phenotype                                                                                                                  Not described                                                                                               [@b62-bmb-51-327]
  M371K                           Missense mutaiton                                        Cardiac pathology (I0ncreased cytoplasmic eosinophilia of cardiomyocytes, focal edema, fragmented cardiomyofibrils and pyknotic-appearing nuclei)                               Not described                                                                                                                                Not described                                                                                               [@b63-bmb-51-327]
  R482Q                           Missense mutaiton                                        Not described                                                                                                                                                                   Familial partial lipodystrophy of the Dunnigan type (FPLD2)                                                                                  Familial partial lipodystrophy of the Dunnigan type (FPLD2). No homozygous patients have been identified.   [@b64-bmb-51-327]
  L530P                           Missense mutaiton                                        Progeroid phenotype. Growth retardation.                                                                                                                                        Indistinguishable phenotype                                                                                                                  Autosomal dominant form of Emery Dreifuss muscular dystrophy (AD-EDMD)                                      [@b65-bmb-51-327]
  G608G                           Mouse G606G base change using BAC system                 Progeroid phenotype. Growth retardation.                                                                                                                                        Indistinguishable phenotype                                                                                                                  Hutchinson--Gilford progeria syndrome (HGPS)                                                                [@b66-bmb-51-327]
  G609G                           Insertion of G609G in exon 11                            Hutchinson--Gilford progeria syndrome (HGPS)                                                                                                                                    Hutchinson--Gilford progeria syndrome (HGPS)                                                                                                 Hutchinson--Gilford progeria syndrome (HGPS)                                                                [@b67-bmb-51-327]

###### 

Mouse model of Lamin B mutations

  Abbreviation   Mutation                                                                                                Homozygous Mouse Phenotype                                                                                                                          Heterozygous Mouse Phenotype   Disease in Human                            Ref
  -------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------- -------------------
  Lamin B1 Δ/Δ   Portion of the rod domain and the entire carboxyl-terminal domain are replaced by gene trap insertion   Embryonic lethal, reduced embryo size and shows abnormal embryo shape. Abnormal lung development and bone ossification in embryo development        No apparent abnormalities      Not described                               [@b68-bmb-51-327]
  Lamin B1 BAC   Overexpresion of Lamin B1 using BAC insertion                                                           Autosomal-dominant leukodystrophy (ADLD). Aberrant myelin formation, axonal degeneration, and demyelination causing cognitive and motor deficits.   No apparent abnormalities      Autosomal-domina nt leukodystrophy (ADLD)   [@b69-bmb-51-327]
